Occurrence of chromosomal abnormalities in Philadelphia chromosome-negative metaphases in patients with chronic-phase chronic myeloid leukemia undergoing TKI treatments. Issue 14 (6th December 2019)

• Record Type: Journal Article
• Authors: Sheng, Guangying; Xue, Mengxing; Wang, Qinrong; Wen, Lijun; Chen, Suning; Zhang, Xinyou; Yang, Xiaofei
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 14(2019)
• Page Start: 3503
• Page End: 3511
• Publication Date: 2019-12-06
• Subjects: Chronic myeloid leukemia -- tyrosine kinase inhibitors -- Philadelphia chromosome-negative metaphases -- monosomy-7 and del(7q) -- prognosis; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2019.1636984
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Forty-three chromosomal abnormalities in Philadelphia-negative metaphases (Ph–CAs) appeared in 35 of 432 patients in chronic phase chronic myeloid leukemia (CP-CML) undergoing tyrosine kinase inhibitor (TKI) treatments. These CAs were mostly common in trisomy-8 (16 cases), trisomy-Y (five cases), and monosomy-7 (five cases). Furthermore, Ph– CAs were significantly associated with higher platelet count (494 × 10 9 /L vs. 326 × 10 9 /L, p = .006), and higher incidence of true clonal evolution in Ph-positive metaphase (22.9% vs. 9.1%, p = .017). Additionally, patients with Ph– CAs had worse rates of complete cytogenetic remission (76% vs. 86%, p = .0091), major molecular remission (55% vs. 76%, p = .001), progression-free survival (47% vs. 86%, p < .001), but a similar overall survival rates compared to those in patients without Ph– CAs. In conclusion, Ph– CAs may predict worse response to TKI therapies and survival in patients with CP-CML, thus requiring close cytogenetic monitoring.